Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Valeant Pharmaceuticals International rose $2.60 (2.9%) to $93.60 on light volume. Throughout the day, 1,374,341 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,887,800 shares. The stock ranged in a price between $91.00-$93.64 after having opened the day at $91.66 as compared to the previous trading day's close of $91.00. Other companies within the Drugs industry that increased today were: Questcor Pharmaceuticals ( QCOR), up 28.4%, Reliv' International ( RELV), up 22.0%, Galectin Therapeutics ( GALT), up 15.3% and GW Pharmaceuticals PLC ADR ( GWPH), up 14.6%.
Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $30.5 billion and is part of the health care sector. Shares are up 52.3% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.